Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX

BACKGROUND: CanAssist Breast (CAB) is a prognostic test for early stage hormone receptor‐positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) breast cancer patients, validated on Indian and Caucasian patients. The 21‐gene signature Oncotype DX (ODX) is the most widely used comme...

Descripción completa

Detalles Bibliográficos
Autores principales: Sengupta, Aditya K., Gunda, Aparna, Malpani, Sukriti, Serkad, Chandra Prakash V., Basavaraj, Chetana, Bapat, Ashok, Bakre, Manjiri M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643688/
https://www.ncbi.nlm.nih.gov/pubmed/33027559
http://dx.doi.org/10.1002/cam4.3495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643688/
https://www.ncbi.nlm.nih.gov/pubmed/33027559
http://dx.doi.org/10.1002/cam4.3495

Ejemplares similares